These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32823003)
1. Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents. Jian Y; Merceron R; De Munck S; Forbes HE; Hulpia F; Risseeuw MDP; Van Hecke K; Savvides SN; Munier-Lehmann H; Boshoff HIM; Van Calenbergh S Eur J Med Chem; 2020 Nov; 206():112659. PubMed ID: 32823003 [TBL] [Abstract][Full Text] [Related]
2. 1-(1-Arylethylpiperidin-4-yl)thymine Analogs as Antimycobacterial TMPK Inhibitors. Jian Y; Hulpia F; D P Risseeuw M; Forbes HE; Caljon G; Munier-Lehmann H; I M Boshoff H; Van Calenbergh S Molecules; 2020 Jun; 25(12):. PubMed ID: 32560578 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents. Jian Y; Hulpia F; Risseeuw MDP; Forbes HE; Munier-Lehmann H; Caljon G; Boshoff HIM; Van Calenbergh S Eur J Med Chem; 2020 Sep; 201():112450. PubMed ID: 32623208 [TBL] [Abstract][Full Text] [Related]
4. 1-(Piperidin-3-yl)thymine amides as inhibitors of Jian Y; Risseeuw MDP; Froeyen M; Song L; Cappoen D; Cos P; Munier-Lehmann H; van Calenbergh S J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1730-1739. PubMed ID: 31822127 [TBL] [Abstract][Full Text] [Related]
5. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents. Song L; Risseeuw MDP; Froeyen M; Karalic I; Goeman J; Cappoen D; Van der Eycken J; Cos P; Munier-Lehmann H; Van Calenbergh S Bioorg Med Chem; 2016 Nov; 24(21):5172-5182. PubMed ID: 27614917 [TBL] [Abstract][Full Text] [Related]
6. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase. Van Calenbergh S; Pochet S; Munier-Lehmann H Curr Top Med Chem; 2012; 12(7):694-705. PubMed ID: 22283813 [TBL] [Abstract][Full Text] [Related]
7. Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors. Song L; Merceron R; Hulpia F; Lucía A; Gracia B; Jian Y; Risseeuw MDP; Verstraelen T; Cos P; Aínsa JA; Boshoff HI; Munier-Lehmann H; Savvides SN; Van Calenbergh S Eur J Med Chem; 2021 Dec; 225():113784. PubMed ID: 34450493 [TBL] [Abstract][Full Text] [Related]
8. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536 [No Abstract] [Full Text] [Related]
9. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Vanheusden V; Munier-Lehmann H; Pochet S; Herdewijn P; Van Calenbergh S Bioorg Med Chem Lett; 2002 Oct; 12(19):2695-8. PubMed ID: 12217356 [TBL] [Abstract][Full Text] [Related]
11. Structure-aided design of inhibitors of Mycobacterium tuberculosis thymidylate kinase. Van Calenbergh S Verh K Acad Geneeskd Belg; 2006; 68(4):223-48. PubMed ID: 17214439 [TBL] [Abstract][Full Text] [Related]
12. Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors. Song L; Merceron R; Gracia B; Quintana AL; Risseeuw MDP; Hulpia F; Cos P; Aínsa JA; Munier-Lehmann H; Savvides SN; Van Calenbergh S J Med Chem; 2018 Apr; 61(7):2753-2775. PubMed ID: 29510037 [TBL] [Abstract][Full Text] [Related]